Evolent Health (EVH) Set to Post Earnings on Thursday

Evolent Health (NYSE:EVH) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Evolent Health to post earnings of $0.06 per share and revenue of $727.06 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, August 6th. The technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The business had revenue of $484.50 million during the quarter, compared to the consensus estimate of $597.70 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. The company’s revenue was up 46.9% compared to the same quarter last year. On average, analysts expect Evolent Health to post ($0.25) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.

Evolent Health Trading Down 3.3%

Shares of Evolent Health stock opened at $4.30 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52. The company has a fifty day simple moving average of $4.18 and a 200-day simple moving average of $3.87. The stock has a market cap of $486.38 million, a price-to-earnings ratio of -0.94 and a beta of 1.03. Evolent Health has a 12-month low of $2.10 and a 12-month high of $6.89.

Insider Activity at Evolent Health

In related news, President Daniel Mccarthy sold 65,892 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total value of $329,460.00. Following the completion of the sale, the president owned 655,133 shares in the company, valued at $3,275,665. This represents a 9.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on EVH shares. Weiss Ratings cut shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 16th. Canaccord Genuity Group dropped their price objective on Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, August 10th. JPMorgan Chase & Co. raised their price objective on Evolent Health from $5.00 to $6.00 and gave the stock an “overweight” rating in a report on Tuesday, August 18th. TD Cowen lifted their target price on Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Finally, Truist Financial reduced their target price on Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Evolent Health currently has an average rating of “Moderate Buy” and an average target price of $5.96.

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.